Superiority of a vitamin B12-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis.

What Was Tested

Researchers studied Cyanocobalamin (Vitamin B12) in the context of psoriasis and psoriatic arthritis in this randomized controlled trial publication.

The wide range of drugs currently available for its treatment could be associated, in the long term, with organ toxicity and adverse events, thus, clinical monitoring throughout treatment is required.

The Psoriasis Area Severity Index (PASI) was determined at baseline (T0), at time points T2 (14 days), T4 (4 weeks), T8 (8 weeks), T12 (12 weeks) and 4 weeks after the end of the wash-out period (F1).

Who Took Part

According to the abstract, 24 patients were involved.

PubMed indexes the participants as young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and single-blind study.

Because people in this Cyanocobalamin (Vitamin B12) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In this single-blind Cyanocobalamin (Vitamin B12) study one party knew the assignments and the other did not.

What Was Measured

Topics PubMed links to this paper include Emollients, Pruritus, Psoriasis, Quality of Life and Vitamin B 12.

Author keywords: hydration and vitamin B12.

What This Means in Plain Language

The paper is a randomized and single-blind study of Cyanocobalamin (Vitamin B12) in 24 patients in people with psoriasis and psoriatic arthritis.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2017 (International journal of immunopathology and pharmacology), a journal based in England.

More context: the Cyanocobalamin (Vitamin B12) compound page, Psoriasis and psoriatic arthritis research.